CLDX Q2 2023 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$268,000+64.4% YoY

Gross Profit

-$26M-9695.5% margin

Operating Income

-$33M-12389.9% margin

Net Income

-$31M-11381.3% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

-72.3%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$299M

Total Liabilities

$22M

Stockholders' Equity

$278M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$268,000	$163,000	+64.4%
Gross Profit	-$26M	-$21M	-26.3%
Operating Income	-$33M	-$36M	+8.8%
Net Income	-$31M	-$36M	+15.3%

Revenue Segments

Grant

$252,00094%

Service

$16,0006%